These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 34459025)

  • 41. Myocardial force development and structural changes associated with monocrotaline induced cardiac hypertrophy and heart failure.
    Korstjens IJ; Rouws CH; van der Laarse WJ; Van der Zee L; Stienen GJ
    J Muscle Res Cell Motil; 2002; 23(1):93-102. PubMed ID: 12363290
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Differences in Effects of Length-Dependent Regulation of Force and Ca
    Lookin O; Balakin A; Protsenko Y
    Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240302
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Opposite diastolic effects of omecamtiv mecarbil versus dobutamine and ivabradine co-treatment in pigs with acute ischemic heart failure.
    Rønning L; Bakkehaug JP; Rødland L; Kildal AB; Myrmel T; How OJ
    Physiol Rep; 2018 Sep; 6(19):e13879. PubMed ID: 30311442
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Mechanistic and structural basis for activation of cardiac myosin force production by omecamtiv mecarbil.
    Planelles-Herrero VJ; Hartman JJ; Robert-Paganin J; Malik FI; Houdusse A
    Nat Commun; 2017 Aug; 8(1):190. PubMed ID: 28775348
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Defective intracellular calcium handling in monocrotaline-induced right ventricular hypertrophy: protective effect of long-term endothelin-A receptor blockade with 2-benzo[1,3]dioxol-5-yl-3-benzyl-4-(4-methoxy-phenyl-)- 4-oxobut-2-enoate-sodium (PD 155080).
    Brunner F; Wölkart G; Haleen S
    J Pharmacol Exp Ther; 2002 Feb; 300(2):442-9. PubMed ID: 11805203
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effects of the cardiac myosin activator Omecamtiv-mecarbil on severe chronic aortic regurgitation in Wistar rats.
    El-Oumeiri B; Mc Entee K; Annoni F; Herpain A; Vanden Eynden F; Jespers P; Van Nooten G; van de Borne P
    BMC Cardiovasc Disord; 2018 May; 18(1):99. PubMed ID: 29783950
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Frequency-dependent myofilament Ca2+ desensitization in failing rat myocardium.
    Lamberts RR; Hamdani N; Soekhoe TW; Boontje NM; Zaremba R; Walker LA; de Tombe PP; van der Velden J; Stienen GJ
    J Physiol; 2007 Jul; 582(Pt 2):695-709. PubMed ID: 17478529
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Heart failure drug changes the mechanoenzymology of the cardiac myosin powerstroke.
    Rohde JA; Thomas DD; Muretta JM
    Proc Natl Acad Sci U S A; 2017 Mar; 114(10):E1796-E1804. PubMed ID: 28223517
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Myosin with hypertrophic cardiac mutation R712L has a decreased working stroke which is rescued by omecamtiv mecarbil.
    Snoberger A; Barua B; Atherton JL; Shuman H; Forgacs E; Goldman YE; Winkelmann DA; Ostap EM
    Elife; 2021 Feb; 10():. PubMed ID: 33605878
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Mechanical load-dependent regulation of gene expression in monocrotaline-induced right ventricular hypertrophy in the rat.
    Kögler H; Hartmann O; Leineweber K; Nguyen van P; Schott P; Brodde OE; Hasenfuss G
    Circ Res; 2003 Aug; 93(3):230-7. PubMed ID: 12842921
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The novel cardiac myosin activator omecamtiv mecarbil increases the calcium sensitivity of force production in isolated cardiomyocytes and skeletal muscle fibres of the rat.
    Nagy L; Kovács Á; Bódi B; Pásztor ET; Fülöp GÁ; Tóth A; Édes I; Papp Z
    Br J Pharmacol; 2015 Sep; 172(18):4506-4518. PubMed ID: 26140433
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Protective effects of hydroalcoholic extract from rhizomes of Cynodon dactylon (L.) Pers. on compensated right heart failure in rats.
    Garjani A; Afrooziyan A; Nazemiyeh H; Najafi M; Kharazmkia A; Maleki-Dizaji N
    BMC Complement Altern Med; 2009 Aug; 9():28. PubMed ID: 19653918
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Orthophosphate increases the efficiency of slow muscle-myosin isoform in the presence of omecamtiv mecarbil.
    Governali S; Caremani M; Gallart C; Pertici I; Stienen G; Piazzesi G; Ottenheijm C; Lombardi V; Linari M
    Nat Commun; 2020 Jul; 11(1):3405. PubMed ID: 32636378
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Safety and tolerability of omecamtiv mecarbil during exercise in patients with ischemic cardiomyopathy and angina.
    Greenberg BH; Chou W; Saikali KG; Escandón R; Lee JH; Chen MM; Treshkur T; Megreladze I; Wasserman SM; Eisenberg P; Malik FI; Wolff AA; Shaburishvili T
    JACC Heart Fail; 2015 Jan; 3(1):22-29. PubMed ID: 25453536
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Population pharmacokinetic-pharmacodynamic modeling of omecamtiv mecarbil, a cardiac myosin activator, in healthy volunteers and patients with stable heart failure.
    Vu T; Ma P; Xiao JJ; Wang YM; Malik FI; Chow AT
    J Clin Pharmacol; 2015 Nov; 55(11):1236-47. PubMed ID: 25951506
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Acceleration of Ca2+ waves in monocrotaline-induced right ventricular hypertrophy in the rat.
    Miura M; Hirose M; Endoh H; Wakayama Y; Sugai Y; Nakano M; Fukuda K; Shindoh C; Shirato K; Shimokawa H
    Circ J; 2011; 75(6):1343-9. PubMed ID: 21467666
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial.
    Teerlink JR; Felker GM; McMurray JJ; Solomon SD; Adams KF; Cleland JG; Ezekowitz JA; Goudev A; Macdonald P; Metra M; Mitrovic V; Ponikowski P; Serpytis P; Spinar J; Tomcsányi J; Vandekerckhove HJ; Voors AA; Monsalvo ML; Johnston J; Malik FI; Honarpour N;
    Lancet; 2016 Dec; 388(10062):2895-2903. PubMed ID: 27914656
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effects of Omecamtiv Mecarbil on Symptoms and Health-Related Quality of Life in Patients With Chronic Heart Failure: Results From the COSMIC-HF Study.
    Felker GM; Solomon SD; McMurray JJV; Cleland JGF; Abbasi SA; Malik FI; Zhang H; Globe G; Teerlink JR;
    Circ Heart Fail; 2020 Dec; 13(12):e007814. PubMed ID: 33176437
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effect of Ejection Fraction on Clinical Outcomes in Patients Treated With Omecamtiv Mecarbil in GALACTIC-HF.
    Teerlink JR; Diaz R; Felker GM; McMurray JJV; Metra M; Solomon SD; Biering-Sørensen T; Böhm M; Bonderman D; Fang JC; Lanfear DE; Lund M; Momomura SI; O'Meara E; Ponikowski P; Spinar J; Flores-Arredondo JH; Claggett BL; Heitner SB; Kupfer S; Abbasi SA; Malik FI;
    J Am Coll Cardiol; 2021 Jul; 78(2):97-108. PubMed ID: 34015475
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cardiac Troponin and Treatment Effects of Omecamtiv Mecarbil: Results From the GALACTIC-HF Study.
    Felker GM; Solomon SD; Metra M; Mcmurray JJV; Diaz R; Claggett B; Lanfear DE; Vandekerckhove H; Biering-Sørensen T; Lopes RD; Arias-Mendoza A; Momomura SI; Corbalan R; Ramires FJA; Zannad F; Heitner SB; Divanji PH; Kupfer S; Malik FI; Teerlink JR
    J Card Fail; 2024 Jun; 30(6):755-763. PubMed ID: 38215932
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.